HER2 ‐positive grade 1 invasive carcinomas of the breast
Histopathology · 2025
DOI: 10.1111/his.15315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Andrew H S Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Histopathology Department, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Aims
The American Society of Clinical Oncology and College of American Pathologists HER2‐guidelines recommend repeat testing for most grade 1 mammary carcinomas that are HER2‐positive in the core biopsy. This study aimed to assess the value of repeat HER2‐testing and the histological features of HER2‐positive grade 1 carcinomas. Methods and results A case‐series of HER2‐results of grade 1 carcinomas was conducted of patients with no pre‐operative systemic treatment over a 5‐year period. HER2‐positive carcinomas had histological review. Twelve HER2‐positive carcinomas were initially reported as grade 1. On review, two were reclassified as grade 2. The remaining 10 carcinomas represented 2% of the 508 grade 1 carcinomas. Eight HER2‐positive grade 1 carcinomas from other years were also studied. HER2‐positive carcinomas more often had marked nuclear pleomorphism (50 versus 6%) and were more often oestrogen receptor‐negative (17 versus 0.8%) and progesterone receptor‐negative (28 versus 8%) compared with HER2‐negative grade 1 carcinomas. Six carcinomas that were HER2 3+ in the core biopsy were also 3+ on repeat assessment. Five of seven carcinomas that were 2+ amplified in the core biopsy were also HER2‐positive in the excision.
Conclusions
HER2‐positive grade 1 carcinomas are uncommon, and more often have marked nuclear pleomorphism and lack oestrogen receptor and progesterone receptor expression compared with HER2‐negative grade 1 carcinomas. A HER2‐poitive result in the core biopsy was confirmed in 11 of 13 tumours that had repeat testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Histopathology Department, Nottingham University Hospitals, City Hospital Campus, Nottingham, UK.
- Source Bioscience plc., Nottingham, UK.
ORCID-Profile: Andrew H S Lee, Ian O Ellis, Emad A Rakha
Zitieren
APA
Lee, A. H. S., Hodi, Z., Abbas, A., Ellis, I. O., & Rakha, E. A. (2025). HER2 ‐positive grade 1 invasive carcinomas of the breast. Histopathology. https://doi.org/10.1111/his.15315
Vancouver
Lee AHS, Hodi Z, Abbas A, Ellis IO, Rakha EA. HER2 ‐positive grade 1 invasive carcinomas of the breast. Histopathology. 2025. doi:10.1111/his.15315
BibTeX
@article{Lee2025,
author = {Lee, Andrew H S and Hodi, Zsolt and Abbas, Areeg and Ellis, Ian O and Rakha, Emad A},
title = {HER2 ‐positive grade 1 invasive carcinomas of the breast},
journal = {Histopathology},
year = {2025},
doi = {10.1111/his.15315}
}
EUVIMED